Literature DB >> 6162505

Interferon production by genetic engineering.

.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 6162505      PMCID： PMC1504560          DOI： 10.1136/bmj.282.6265.674-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  13 in total

1.  The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha.

Authors:  S Nagata; N Mantei; C Weissmann
Journal:  Nature       Date:  1980-10-02       Impact factor: 49.962

2.  A family of structural genes for human lymphoblastoid (leukocyte-type) interferon.

Authors:  G Allen; K H Fantes
Journal:  Nature       Date:  1980-10-02       Impact factor: 49.962

3.  A monoclonal antibody for large-scale purification of human leukocyte interferon.

Authors:  D S Secher; D C Burke
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

4.  Expression of human fibroblast interferon gene in Escherichia coli.

Authors:  R Derynck; E Remaut; E Saman; P Stanssens; E De Clercq; J Content; W Fiers
Journal:  Nature       Date:  1980-09-18       Impact factor: 49.962

5.  Expression in Escherichia coli of chemically synthesized genes for human insulin.

Authors:  D V Goeddel; D G Kleid; F Bolivar; H L Heyneker; D G Yansura; R Crea; T Hirose; A Kraszewski; K Itakura; A D Riggs
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

6.  Synthesis in E. coli of a polypeptide with human leukocyte interferon activity.

Authors:  S Nagata; H Taira; A Hall; L Johnsrud; M Streuli; J Ecsödi; W Boll; K Cantell; C Weissmann
Journal:  Nature       Date:  1980-03-27       Impact factor: 49.962

7.  At least three human type alpha interferons: structure of alpha 2.

Authors:  M Streuli; S Nagata; C Weissmann
Journal:  Science       Date:  1980-09-19       Impact factor: 47.728

8.  Effect of interferon-alpha 1 from E. coli on some cell functions.

Authors:  M G Masucci; R Szigeti; E Klein; G Klein; J Gruest; L Montagnier; H Taira; A Hall; S Nagata; C Weissmann
Journal:  Science       Date:  1980-09-19       Impact factor: 47.728

9.  Human leukocyte interferon produced by E. coli is biologically active.

Authors:  D V Goeddel; E Yelverton; A Ullrich; H L Heyneker; G Miozzari; W Holmes; P H Seeburg; T Dull; L May; N Stebbing; R Crea; S Maeda; R McCandliss; A Sloma; J M Tabor; M Gross; P C Familletti; S Pestka
Journal:  Nature       Date:  1980-10-02       Impact factor: 49.962

10.  Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men.

Authors:  H Keen; A Glynne; J C Pickup; G C Viberti; R W Bilous; R J Jarrett; R Marsden
Journal:  Lancet       Date:  1980-08-23       Impact factor: 79.321
View more
  4 in total

Review 1.  Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.

Authors:  Maria Kalafateli; Elena Buzzetti; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-13

Review 2.  Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis.

Authors:  Konstantinos Mantzoukis; Manuel Rodríguez-Perálvarez; Elena Buzzetti; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-21

3.  Pharmacological interventions for acute hepatitis C infection.

Authors:  Maria Kalafateli; Elena Buzzetti; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-12-03

4.  Human myelomeningocele risk and ultra-rare deleterious variants in genes associated with cilium, WNT-signaling, ECM, cytoskeleton and cell migration.

Authors:  K S Au; L Hebert; P Hillman; C Baker; M R Brown; D-K Kim; K Soldano; M Garrett; A Ashley-Koch; S Lee; J Gleeson; J E Hixson; A C Morrison; H Northrup
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.